Decreased MALL expression negatively impacts colorectal cancer patient survival

The aim of the present study was to determine whether MALL expression is associated with colon cancer progression and patient survival. MALL mRNA expression was reduced in the tumor tissues of 70% of the colon cancer patients and 75% of the rectal cancer patients as compared to their normal tissues. MALL protein was also significantly reduced in the tumor tissues of colon cancer patients (P < 0.001). Increased LOH and methylation of MALL was observed in tumor tissues as compared to normal tissues. Reduced MALL expression was associated with vessin invasion, disease recurrence and metastasis or death (P ≤ 0.027). Furthermore, patients with MALL-negative tumors had significantly decreased overall survival (OS) and disease-free survival (DFS) (P < 0.008 and P < 0.011, respectively). Univariate analysis indicated that MALL expression was significantly associated with OS and DFS. Finally, overexpression of MALL suppressed HCT116 and SW480 cell proliferation and inhibited HCT116 migration. MALL may play a role in colorectal cancer progression as suppression of its expression in tumor tissues negatively impacts colorectal cancer patient survival. Further analyses are required to determine if reduced MALL expression is due to LOH and/or methylation.

[1]  Fudong Yu,et al.  PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy , 2014, Oncotarget.

[2]  Qi-Hong Jiang,et al.  Radixin Enhances Colon Cancer Cell Invasion by Increasing MMP-7 Production via Rac1-ERK Pathway , 2014, TheScientificWorldJournal.

[3]  N. Schaeren-Wiemers,et al.  MAL Overexpression Leads to Disturbed Expression of Genes That Influence Cytoskeletal Organization and Differentiation of Schwann Cells , 2014, ASN neuro.

[4]  C. Probert,et al.  Population-based screening in colorectal cancer - current practice and future developments: faecal biomarkers review. , 2014, Journal of gastrointestinal and liver diseases : JGLD.

[5]  P. Rørth,et al.  The core and conserved role of MAL is homeostatic regulation of actin levels , 2014, Genes & development.

[6]  J. Goldenring.  A central role for vesicle trafficking in epithelial neoplasia: intracellular highways to carcinogenesis , 2013, Nature Reviews Cancer.

[7]  Mariska Bierkens,et al.  CADM1 and MAL promoter methylation levels in hrHPV‐positive cervical scrapes increase proportional to degree and duration of underlying cervical disease , 2013, International journal of cancer.

[8]  D. Altomare,et al.  New strategies for colorectal cancer screening. , 2013, World journal of gastroenterology.

[9]  K. Shiraishi,et al.  Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer , 2013, Oncology reports.

[10]  Hua-mei Tang,et al.  Phospholipase C epsilon plays a suppressive role in incidence of colorectal cancer , 2012, Medical Oncology.

[11]  Dawei Li,et al.  Reduced Expression of PER3 Is Associated with Incidence and Development of Colon Cancer , 2012, Annals of Surgical Oncology.

[12]  Johannes Berkhof,et al.  Combined CADM1 and MAL promoter methylation analysis to detect (pre‐)malignant cervical lesions in high‐risk HPV‐positive women , 2011, International journal of cancer.

[13]  Veerle M.H. Coupé,et al.  Combined Promoter Methylation Analysis of CADM1 and MAL: An Objective Triage Tool for High-Risk Human Papillomavirus DNA–Positive Women , 2011, Clinical Cancer Research.

[14]  Ming Yan,et al.  Epigenetic silencing of MAL, a putative tumor suppressor gene, can contribute to human epithelium cell carcinoma , 2010, Molecular Cancer.

[15]  B. Larsen.  [Colorectal cancer screening]. , 2010, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[16]  A. Berchuck,et al.  Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer , 2010, International journal of cancer.

[17]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[18]  Saskia M Wilting,et al.  Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis , 2009, The Journal of pathology.

[19]  A. Ullrich,et al.  Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errfi-1 induction. , 2009, Molecular cell.

[20]  Jun Xia,et al.  IMP3 Is a Novel Prognostic Marker that Correlates with Colon Cancer Progression and Pathogenesis , 2009, Annals of Surgical Oncology.

[21]  H. Grabsch,et al.  MAL promoter hypermethylation as a novel prognostic marker in gastric cancer , 2008, British Journal of Cancer.

[22]  Chi-Ying F. Huang,et al.  PhosphoPOINT: a comprehensive human kinase interactome and phospho-protein database , 2008, ECCB.

[23]  Hua-mei Tang,et al.  Gene‐expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene‐expression analyses , 2008, Cancer.

[24]  R. Lothe,et al.  DNA hypermethylation of MAL: a promising diagnostic biomarker for colorectal tumors. , 2007, Gastroenterology.

[25]  Jin Gu,et al.  Changing patterns of colorectal cancer in China over a period of 20 years. , 2005, World journal of gastroenterology.

[26]  C. Ko,et al.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.

[27]  M. Marazuela,et al.  Expression of MAL and MAL2, two elements of the protein machinery for raft-mediated transport, in normal and neoplastic human tissue. , 2004, Histology and histopathology.

[28]  M. Marazuela,et al.  Expression of MAL2, an Integral Protein Component of the Machinery for Basolateral-to-Apical Transcytosis, in Human Epithelia , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  G Rice,et al.  Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR–β1 integrin complex in colon cancer cells , 2003, British Journal of Cancer.

[30]  Takaaki Masuda,et al.  MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway , 2003, Oncogene.

[31]  A. Dopazo,et al.  Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. , 2002, The American journal of pathology.

[32]  L. Ellis,et al.  Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. , 1999, Cancer research.

[33]  K. Simons,et al.  VIP17/MAL, a lipid raft-associated protein, is involved in apical transport in MDCK cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Puertollano,et al.  The MAL Proteolipid Is Necessary for Normal Apical Transport and Accurate Sorting of the Influenza Virus Hemagglutinin in Madin-Darby Canine Kidney Cells , 1999, The Journal of cell biology.

[35]  D. Sir.  DNA Hypermethylation of MAL :A Promising Diagnostic Biomarker for Colorectal Tumors , 2007 .

[36]  M. Choti,et al.  Colon cancer clinical practice guidelines in oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[37]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 1995. , 2002, European journal of cancer.